Objective -The efficacy of sarolaner was evaluated against ear mite infestation caused by Otodectes cynotis in dogs and compared with topical moxidectin/imidacloprid in a single-masked, multi-centre field study.
Introduction
Otodectic mange caused by Otodectes cynotis is highly contagious and one of the most common mite infestations in dogs, with up to 6.7% of dog populations infested in some reports. [1] [2] [3] [4] [5] Mites live on the skin surface primarily, deep inside the external ear canal; they may survive in the environment for several weeks; ectopic infestations are reported particularly on the head, tail and neck. 6, 7 Clinical signs may include erythema, a dark brown, coffeeground-like, ceruminous otic exudate and varying levels of pruritus. [7] [8] [9] Two licensed spot-on treatments containing the macrocyclic lactones moxidectin and selamectin are available worldwide for the treatment of ear mite infestation in the dog. [10] [11] [12] [13] Both have long residual activity and act systemically covering ectopic infestation. 9 Good treatment results also have been reported for orally administered and systemically active drugs of the isoxazoline class in small-scale studies with induced infestation with ear mites in dogs. [14] [15] [16] Sarolaner is approved in Europe, in combination with selamectin, for the treatment of O. cynotis infestations in cats. 17 In this study, the efficacy and safety of sarolaner was investigated in comparison to imidacloprid/moxidectin, in a large-scale field study in dogs with ear mite infestation, to support the licensing of sarolaner (Simparicaâ Chewable Tablets, Zoetis; Parsippany, NJ, USA) for the treatment of Otodectes infestations in dogs.
Methods
A randomized, single-masked, multi-centre clinical study with a positive control was conducted in France (11 sites), Hungary (six sites), Portugal (10 sites) and Italy (three sites). The study was conducted in compliance with Good Clinical Practice. 18 The study protocol was reviewed and approved by the Zoetis Ethics Review Assessment team. Masking was accomplished by assuring that all personnel conducting efficacy and safety evaluations were unaware of the treatment allocation. Dedicated dispensers administered treatments but were not involved in other study activities or analyses; the investigators were unaware of treatment allocation.
Animals
Client-owned dogs were enrolled with their owners' written consent if they showed clinical signs of otoacariasis and had visible live ear mites present in at least one ear upon otoscopic examination. Dogs were not enrolled if they were pregnant, lactating, intended for breeding or were less than 8 weeks old (as per approval of sarolaner in Europe), were receiving systemic or topical antimicrobials or antiinflammatory agents and if they have been treated with an ectoparasiticide that had residual efficacy against O. cynotis at the time of enrolment. In multi-dog households, the dog with the most severe O. cynotis infestation was included in efficacy and safety evaluations as the primary patient. Other household dogs were enrolled as supplementary patients independent of whether or not they showed signs of ear mite infestations, received the same treatment as the primary patient but were only included in safety evaluations. All dogs completed the study when no live mites were found in the ears of the primary dog or on day 60 at the latest.
Treatment administration
Primary dogs were allocated in a ratio of 2:1 to one of two treatment groups to receive sarolaner or imidacloprid/moxidectin, respectively, in a randomized block design with one-way treatment structure replicated in multiple clinics. Treatments were administered by the dispenser on day 0 (first treatment received), and if necessary on day 30. Simparicaâ Chewable Tablets (Zoetis) were administered orally according to the approved dosing table in the SPC to deliver the recommended dose of 2-4 mg/kg sarolaner. There were no restrictions regarding the time of dosing to the feeding time of the patients. Advocateâ Spot On Dog (Bayer; Leverkusen, Germany) was used as a positive control product and was administered topically following the approved label directions, to deliver at least 10 mg/kg bodyweight imidacloprid and 2.5 mg/kg bodyweight moxidectin.
Efficacy evaluation
Otoscopic examination was performed by a veterinarian on both ears of all primary dogs on days 0, 14 and 30, and, if applicable, on day 60. A deviation of five days from these scheduled visit days was allowed. If no live mites were visible (larvae, nymphs or adults) in any of the ears then a swab sample was taken from one ear and was examined under a microscope for the presence of ear mites. If no viable mites (capable of movement) were found in the swab sample, then the second ear was also swabbed. If viable mites were observed during the otoscopic examination, no ear swab was taken from any of the ears. The presence of O. cynotis mites was recorded without quantification.
Clinical signs of otoacariasis including head shaking, pruritus/ear scratching, trauma or alopecia of the pinnae, and erythema, ulceration and debris in the ear canals was evaluated for all primary dogs by the study veterinarian on days 0, 14 and 30, and, if applicable, on day 60. The severity of these clinical signs was graded in four levels as absent, mild, moderate or severe. The cleaning of the ears either mechanically or with otic solutions was strictly prohibited in the primary dogs throughout the study period.
Safety
A physical examination by a veterinarian was performed at each visit and owners were asked about abnormal heath observations between the visits.
Data Analysis
All calculations were performed using SAS v9.4 (SAS Institute; Cary, NC, USA). The individual dog was the experimental unit. Dogs that completed a visit more than five days outside the scheduled visit date and dogs in which the absence of mites was not established because they did not have a swab sample evaluated after negative otoscopic examinations, were not included in the analysis at that respective visit.
Parasitological cure rate, defined as the percentage of dogs free of live mites was calculated at each post-treatment visit and at study completion. A generalized mixed linear model for repeated measures for a binomial distribution with logit link was used to analyse the parasitological cure rate for days 14 and 30. The model included fixed effects for treatment, time and treatment-by-time. The random effects included clinic, block within clinic, the interaction of clinic and treatment, and the interaction of clinic, treatment and time. Back-transformed least squares means were used as estimates for parasitological cure rates for each treatment at each time point. Non-inferiority of sarolaner compared to moxidectin/imidacloprid for parasitological cure rate was assessed at the one-sided 0.025 significance level on days 14 and 30. The non-inferiority margin of 15% was used. Additionally, the proportion of dogs with clinical signs of otoacariasis was calculated at each visit for each lesion type by severity grade.
Results

Animals
In total, 163 primary dogs and 120 supplementary dogs received sarolaner, and 78 primary and 53 supplementary dogs received moxidectin/imidacloprid. In total, four primary (one in the sarolaner group and three in the 
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Number and proportion of dogs with no live mites (parasitological cure) at each visit and at study completion treated monthly with oral doses of sarolaner or topical applications of imidacloprid plus moxidectin. The details of the non-inferiority test that were conducted on days 14 and 30 are also shown for the group comparison. *Estimated difference between treatment proportions on parasitological cure rates (estimated from back-transformed least squares means). † Sarolaner was non-inferior to moxidectin/imidacloprid at the one-sided 2.5% alpha level because the lower limit of the 95% confidence interval is greater than -0.15.
moxidectin/imidacloprid group) and four supplementary dogs (two in each group) did not complete the study. In the sarolaner-treated group, one primary dog was withdrawn one day after the first treatment administration because the supplementary dog in the same household did not meet the inclusion criteria. One additional supplementary dog in this group died on day 20 due to an unrelated disease. In the moxidectin/imidacloprid group one primary dog died on day 12 in a dog fight and the two supplementary dogs living in the same household were thus withdrawn. Additionally, one primary dog was withdrawn due to lack of efficacy on day 22 and one primary dog was withdrawn because of owner noncompliance. The mean age of the dogs at enrolment was 3.8 years in the sarolaner group and 3.9 years in the moxidectin/imidacloprid group. In the sarolaner group, 71.0% of the dogs were pure-breds and 29.0% were mixed breeds, whereas in the moxidectin/imidacloprid group 68.7% were pure-breds and 31.3% were mixed breeds. In the sarolaner group, 50.9% of the dogs were females and 49.1% were males, whereas in the moxidectin/imidacloprid group 52.7% were females and 47.3% were males. At enrolment the mean body weight of the dogs was 18.4 and 17.3 kg in the sarolaner and the moxidectin/imidacloprid groups, respectively.
Efficacy
Parasitological cure rates Parasitological cure rates in each treatment group at each evaluated time point and overall at study completion are summarized in Table 1 . The parasitological cure rate for sarolaner was non-inferior to moxidectin/imidacloprid at both days 14 and 30 as detailed in Table 1 . Seventeen of 163 dogs (10.4%) receiving sarolaner and 28 of 78 dogs (34.6%) receiving moxidectin/imidacloprid required a second treatment on day 30. Out of these, 15 sarolaner-treated and 27 moxidectin/imidaclopridtreated dogs were included in the efficacy evaluations on day 60.
Clinical signs of otoacariasis
One primary dog in each treatment group received concurrent treatment with systemic antibiotics following enrolment that could have aided in the resolution of clinical signs of otoacariasis. Their ear lesion scores recorded after the concurrent treatment were thus all excluded from the assessment of the clinical sign progression. The proportion of dogs showing head shaking, pruritus/ear scratching, trauma or alopecia of the pinnae, and erythema, ulceration and debris in the ear canals, in each treatment group, at each evaluated time point and overall at study completion, are summarized in Table 2 .
Health observations
Abnormal health events were reported in seven sarolaner-treated and six moxidectin/imidacloprid-treated dogs. In the sarolaner-treated group, it included one dog each with bilateral conjunctivitis, urinary tract infection, gastrointestinal parasitosis, gastrointestinal foreign body, hot spot, and one dog with mild apathy and altered appetite; none were considered to be drug-related. One dog died suddenly due to a suspected cardiac condition. In the moxidectin/imidacloprid group, there was one dog each with a foreign body in the ear, flea infestation, decubital ulcer on the amputation site of the leg, umbilical hernia and one dog died in a dog fight; none were considered to be drug-related. One additional dog had worsening ear pruritus with resulting ear ulceration and was withdrawn from the study because of lack of efficacy.
Discussion
The study demonstrated non-inferiority of sarolaner to moxidectin/imidacloprid in the treatment of canine ear mite infestations regarding parasitological cure rates on days 14 and 30, corroborating efficacy reported previously using induced mite infestation.
14 After a single oral treatment with sarolaner, 90.5% of the dogs were free of mites 30 days later, whereas after two monthly treatments all but one dog achieved parasitological cure in the sarolaner group.
In comparison, in the current study, topical moxidectin/ imidacloprid did not achieve parasitological cure in 36.5% of the dogs at 30 days after a single treatment. This level of efficacy of moxidectin/imidacloprid is comparable to two previous studies where 31.4% and 29.4% of the moxidectin/imidacloprid-treated dogs still harboured mites after a single treatment. 10, 13 Following two monthly treatments, 12.2% of the moxidectin/imidacloprid treated dogs still harboured mites in the current study. In two previous studies, similar proportions of dogs (18% and 14.3%) did not reach parasitological cure after two monthly topical treatments with moxidectin/imidacloprid. 10, 13 The elimination of mites after sarolaner administration was accompanied by a marked improvement in the signs of otoacariasis. This improvement was presumed to be solely due to the miticide treatment because no concomitant treatments with any topical or systemic products were allowed during the study. It is difficult to compare the impact of treatments on clinical signs across different studies. These were either not assessed, the results were not reported in detail or a different quantitative scoring system was used. 10, 11, 13 In the current study there was a relatively small improvement in the proportion of dogs with debris in the ear canal in both treatment groups. This is not surprising, considering that cleaning of ear canals was prohibited during the study period. Under clinical conditions it is recommended to clean ears because debris may be irritating and favour secondary infections. 5, 8 None of the adverse reactions were considered to be drug-related, which indicates that oral sarolaner and topical imidacloprid/moxidectin are safe and effective treatments for otoacariasis in dogs.
The results from this non-inferiority study indicated that a single oral administration of sarolaner to dogs was effective in eliminating ear mites and resolving clinical signs of the disease, and may be a convenient treatment option at monthly dosing.
clinques de l'otacariose se sont am elior es au cours de l' etude pour les deux groupes. Il n'y a pas eu d'effet secondaire li e au traitement. Aucun effet secondaire li e au traitement n'a et e observ e. Conclusions -Une administration orale unique de sarolaner a et e sure et hautement efficace dans le traitement d'infestation a O. cynotis chez le chien.
Resumen
Introducci on -existen diversos tratamientos disponibles para las infestaciones de acaros del o ıdo en perros. Objetivo -se evalu o la eficacia de sarolaner frente a la infestaci on de acaros del o ıdo causada por Otodectes cynotis en perros en un estudio de campo al azar, simple-enmasacarado y multic entrico. Animales -Perros de propietarios particulares con infestaci on por O. cynotis fueron tratados mensualmente con sarolaner oral (n = 163) o moxidectin / imidacloprid t opico (n = 78). M etodos -se evalu o la presencia de acaros en los canales auditivos y los signos cl ınicos asociados con otoacariasis (incluyendo temblores de cabeza, prurito/rascado del o ıdo, traumatismo o alopecia de las porejas, y eritema, ulceraci on y detritus en los canales auditivos) en los d ıas 0, 14 y 30, y si correspond ıa, en el d ıa 60. Los perros se consideraron curados de la infestaci on de acaros despu es de uno (en el d ıa 0) o dos (en los d ıas 0 y 30) tratamientos mensuales si no se encontraron acaros vivos en ninguno de los o ıdos. La no inferioridad se evalu o los d ıas 14 y 30. Resultados -La curaci on parasitol ogica se logr o en un 76,4%, 90,5% y 93,3% de los perros tratados con sarolaner y en 53,9%, 63,5% y 66,7% de los tratados con moxidectina/imidacloprid en los d ıas 14, 30 y 60, respectivamente. Al finalizar el estudio, el d ıa 60 a m as tardar, se logr o la curaci on parasitol ogica en general en el 99,4% de los casos tratados con sarolaner y el 87,8% de los tratados con moxidectina/imidacloprid. La tasa de curaci on parasitol ogica para sarolaner no fue inferior a moxidectin/imidacloprid en los d ıas 14 y 30. Los signos cl ınicos de otoacariasis mejoraron a lo largo del estudio en ambos grupos. No hubo eventos adversos relacionados con el tratamiento. Conclusiones -una sola administraci on oral de sarolaner fue segura y altamente efectiva en el tratamiento de la infestaci on de O. cynotis en perros.
